Aeris Therapeutics Inc. landed CE Mark approval for its AeriSeal emphysematous lung sealant system in the European Union.
The Woburn, Mass.-based company said its foam sealant, which doctors deliver through a bronchoscope, is a surgical alternative for the treatment of advanced emphysema, a chronic obstructive pulmonary disease primarily caused by smoking cigarettes. In cases of advanced lung diseases, invasive treatment options include lung transplantation and lung volume reduction surgery, according to the company.
"[The CE Mark] allows us to promptly address immediate demand for new therapies for emphysema in the EU, a potential $7 billion market opportunity," said Aeris CEO Dr. David Dove in prepared remarks.
